Senti Biosciences Inc.

Senti Biosciences has completed its conversion into a holding company: all common shares were automatically converted on a 1:1 basis into shares of Senti Biosciences Holdings and remain listed on the Nasdaq Capital Market under the ticker SNTI, now with a new CUSIP. The merger was effected by combining with the wholly owned subsidiary Senti Biosciences Merger Sub under Delaware law without requiring shareholder approval; outstanding warrants were similarly converted into rights to Holdings shares. The company expects no material changes to consolidated assets, business activities, or operations and treats the transaction as tax-free for U.S. federal income tax purposes. » More on de.investing.com

Senti Biosciences publishes a study in Cell Systems on NOT-gate–controlled chimeric antigen receptors (CAR) in T and NK cells, evaluating more than 60 designs. The research identifies LIR1-based inhibitory CARs as regulators, shows reduced exhaustion markers and sustained cytotoxic activity after repeated antigen exposure, and demonstrates tumor cell elimination while sparing protective non-tumor cells in an in vivo model. The company has filed a patent application and links the results to prior clinical data for SENTI-202. Senti is in the clinical stage; its stock trades near a 52-week low and the company reports negative EBITDA. » More on de.investing.com

Senti Biosciences presented data from the ongoing SENTI‑202 study in relapsed/refractory AML: at the recommended phase‑2 dose the overall response rate was 50% and the complete remission rate 42%, with most remissions MRD‑negative. The therapy showed selective activity against AML blasts with good tolerability and no dose‑limiting toxicities. The FDA granted SENTI‑202 RMAT status; Senti plans registrational studies but continues to report high cash burn and net losses. » More on de.investing.com